表紙
市場調查報告書

全球抗菌治療市場:2020年∼2024年

Global Antimicrobial Therapeutics Market 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 934841
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
全球抗菌治療市場:2020年∼2024年 Global Antimicrobial Therapeutics Market 2020-2024
出版日期: 2020年05月02日內容資訊: 英文 120 Pages
簡介

全球抗菌治療市場在2020年∼2024年間,預測將成長到4,230萬美元的規模,在預測期間內預計將以6%的年複合成長率擴大的事被預測。最近的藥品批准和強大的銷售渠道,政府的努力以及對微生物疾病意識的增強推動了該市場的成長。

本報告提供全球抗菌治療市場調查,提供市場整體分析,市場規模與預測,趨勢,成長要素,課題,以及供應商分析等整體性資訊wo。

目錄

摘要整理

市場形勢

市場規模

  • 市場定義
  • 市場區隔分析
  • 2019年的市場規模
  • 市場預測:從2019年∼2024年的預測

波特的五力分析

各用途市場區分

  • 市場區隔
  • 各用途比較
  • 抗病毒藥物 - 市場規模與預測
  • 抗菌劑 - 市場規模與預測
  • 抗真菌藥物 - 市場規模與預測
  • 除蟲藥 - 市場規模與預測
  • 各用途的市場機會

客戶形勢

各地區形勢

  • 各地區區分
  • 各地區比較
  • 北美 - 市場規模與預測
  • 歐洲 - 市場規模與預測
  • 亞太地區 - 市場規模與預測
  • 其他地區 - 市場規模與預測
  • 主要國家
  • 地區的市場機會
  • 交易量的成長要素 - 需求主導成長
  • 交易量的成長要素 - 外部要素
  • 市場課題
  • 市場趨勢

業者情勢

  • 業者情勢
  • 創造性破壞狀況

供應商分析

  • 交易廠商
  • 供應商的市場定位
  • AbbVie Inc.
  • CSL Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi

附錄

目錄
Product Code: IRTNTR43391

Technavio has been monitoring the antimicrobial therapeutics market and it is poised to grow by $ 42.30 million during 2020-2024 progressing at a CAGR of 6% during the forecast period. Our reports on antimicrobial therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the recent drug approvals and robust pipeline, initiatives from government agencies, and rising awareness about microbial diseases. In addition, recent drug approvals and robust pipeline is anticipated to boost the growth of the market as well.

The antimicrobial therapeutics market analysis includes application segment and geographic landscapes

Technavio's ‘ antimicrobial therapeutics market ’ is segmented as below:

By Application

  • Antiviral
  • Antibacterial
  • Antifungal
  • Antiparasitic

By Geographic Landscape:

  • North America
  • Europe
  • APAC
  • ROW

This study identifies the increase in R&D of therapeutic vaccines as one of the prime reasons driving the antimicrobial therapeutics market growth during the next few years. Also, increased disease diagnostic modalities, and increasing research on combination therapies will lead to sizable demand in the market.

"Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our antimicrobial therapeutics market covers the following areas:

  • Antimicrobial therapeutics market sizing
  • Antimicrobial therapeutics market forecast
  • Antimicrobial therapeutics market industry analysis"

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading antimicrobial therapeutics market vendors that include AbbVie Inc., CSL Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., and Sanofi. Also, the antimicrobial therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Application

  • Market segments
  • Comparison by Application
  • Antiviral - Market size and forecast 2019-2024
  • Antibacterial - Market size and forecast 2019-2024
  • Antifungal - Market size and forecast 2019-2024
  • Antiparasitic - Market size and forecast 2019-2024
  • Market opportunity by Application

Customer Landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • APAC - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography
  • Volume driver - Demand led growth
  • Volume driver - External factors
  • Market challenges
  • Market trends

Vendor Landscape

  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • AbbVie Inc.
  • CSL Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibit

  • 1: Key Finding 1
  • 2: Key Finding 2
  • 3: Key Finding 3
  • 4: Key Finding 5
  • 5: Key Finding 6
  • 6: Key Finding 7
  • 7: Key Finding 8
  • 8: Parent market
  • 9: Market characteristics
  • 10: Offerings of vendors included in the market definition
  • 11: Market segments
  • 12: Global - Market size and forecast 2019 - 2024 ($ million)
  • 13: Global market: Year-over-year growth 2019 - 2024 (%)
  • 14: Five forces analysis 2019 & 2024
  • 15: Bargaining power of buyers
  • 16: Bargaining power of suppliers
  • 17: Threat of new entrants
  • 18: Threat of substitutes
  • 19: Threat of rivalry
  • 20: Market condition - Five forces 2019
  • 21: Application - Market share 2019-2024 (%)
  • 22: Comparison by Application
  • 23: Antiviral - Market size and forecast 2019-2024 ($ million)
  • 24: Antiviral - Year-over-year growth 2019-2024 (%)
  • 25: Antibacterial - Market size and forecast 2019-2024 ($ million)
  • 26: Antibacterial - Year-over-year growth 2019-2024 (%)
  • 27: Antifungal - Market size and forecast 2019-2024 ($ million)
  • 28: Antifungal - Year-over-year growth 2019-2024 (%)
  • 29: Antiparasitic - Market size and forecast 2019-2024 ($ million)
  • 30: Antiparasitic - Year-over-year growth 2019-2024 (%)
  • 31: Market opportunity by Application
  • 32: Customer landscape
  • 33: Market share by geography 2019-2024 (%)
  • 34: Geographic comparison
  • 35: North America - Market size and forecast 2019-2024 ($ million)
  • 36: North America - Year-over-year growth 2019-2024 (%)
  • 37: Europe - Market size and forecast 2019-2024 ($ million)
  • 38: Europe - Year-over-year growth 2019-2024 (%)
  • 39: APAC - Market size and forecast 2019-2024 ($ million)
  • 40: APAC - Year-over-year growth 2019-2024 (%)
  • 41: ROW - Market size and forecast 2019-2024 ($ million)
  • 42: ROW - Year-over-year growth 2019-2024 (%)
  • 43: Key leading countries
  • 44: Market opportunity by geography ($ million)
  • 45: Impact of drivers and challenges
  • 46: Vendor landscape
  • 47: Landscape disruption
  • 48: Industry risks
  • 49: Vendors covered
  • 50: Market positioning of vendors
  • 51: AbbVie Inc. - Overview
  • 52: AbbVie Inc. - Business segments
  • 53: AbbVie Inc. - Key offerings
  • 54: AbbVie Inc. - Key customers
  • 55: AbbVie Inc. - Segment focus
  • 56: CSL Ltd. - Overview
  • 57: CSL Ltd. - Business segments
  • 58: CSL Ltd. - Key offerings
  • 59: CSL Ltd. - Key customers
  • 60: CSL Ltd. - Segment focus
  • 61: F. Hoffmann-La Roche Ltd. - Overview
  • 62: F. Hoffmann-La Roche Ltd. - Business segments
  • 63: F. Hoffmann-La Roche Ltd. - Key offerings
  • 64: F. Hoffmann-La Roche Ltd. - Key customers
  • 65: F. Hoffmann-La Roche Ltd. - Segment focus
  • 66: Gilead Sciences Inc. - Overview
  • 67: Gilead Sciences Inc. - Product and service
  • 68: Gilead Sciences Inc. - Key offerings
  • 69: Gilead Sciences Inc. - Key customers
  • 70: Gilead Sciences Inc. - Segment focus
  • 71: GlaxoSmithKline Plc - Overview
  • 72: GlaxoSmithKline Plc - Business segments
  • 73: GlaxoSmithKline Plc - Key offerings
  • 74: GlaxoSmithKline Plc - Key customers
  • 75: GlaxoSmithKline Plc - Segment focus
  • 76: Johnson & Johnson - Overview
  • 77: Johnson & Johnson - Business segments
  • 78: Johnson & Johnson - Key offerings
  • 79: Johnson & Johnson - Key customers
  • 80: Johnson & Johnson - Segment focus
  • 81: Merck & Co. Inc. - Overview
  • 82: Merck & Co. Inc. - Business segments
  • 83: Merck & Co. Inc. - Key offerings
  • 84: Merck & Co. Inc. - Key customers
  • 85: Merck & Co. Inc. - Segment focus
  • 86: Novartis AG - Overview
  • 87: Novartis AG - Business segments
  • 88: Novartis AG - Key offerings
  • 89: Novartis AG - Key customers
  • 90: Novartis AG - Segment focus
  • 91: Pfizer Inc. - Overview
  • 92: Pfizer Inc. - Business segments
  • 93: Pfizer Inc. - Key offerings
  • 94: Pfizer Inc. - Key customers
  • 95: Pfizer Inc. - Segment focus
  • 96: Sanofi - Overview
  • 97: Sanofi - Business segments
  • 98: Sanofi - Key offerings
  • 99: Sanofi - Key customers
  • 100: Sanofi - Segment focus
  • 101: Currency conversion rates for US$
  • 102: Research Methodology
  • 103: Validation techniques employed for market sizing
  • 104: Information sources
  • 105: List of abbreviations